20.6 C
New York
Wednesday, June 10, 2026

Tag: medication

newssourceFORcompanyinformationcontent1marketreleases

Nursing Home Abuse Center Responds to CMS Repeal of Federal Nursing Home Staffing Minimums

NEWTON, Mass., June 8, 2026 /PRNewswire/ -- The Nursing Home Abuse Center is providing context for residents and families following a federal policy shift that...

National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Agnostic eGFR in Medication Decision-Making

NEW YORK, June 8, 2026 /PRNewswire/ -- A coalition of leading U.S. pharmacy organizations, in collaboration with the National Kidney Foundation (NKF), is urging...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring

New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care SettingsNEW ORLEANS, June 6, 2026 /PRNewswire/ -- A new...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

‘Alberta Ag-Plastics. Recycle It!’ Shortlisted for 35th Annual Emerald Awards for Environmental Excellence

LETHBRIDGE, Alberta, June 05, 2026 (GLOBE NEWSWIRE) -- The ‘Alberta Ag-Plastic. Recycle It!’ program has been included in the shortlist for the 35th Annual Emerald Awards, presented by the Alberta Emerald Foundation (AEF), recognizing environmental excellence across the province. The shortlist represents the top projects and organizations selected from this year’s nominations, highlighting Alberta’s impact, innovation, and leadership in the environmental space.

13 Top Press Releases from May

Including United's offer for Spirit customers, eBay's response to GameStop's acquisition proposal, and a new partnership between major telecom providers.Plus, a recap of May's...

Herbalgy “TO-Go” Summer Treat: Keung To-Themed Gelato Truck

Free Gelato + Exclusive Fan Support Hand Fan, Stay Cool. Stay "TO". One Receipt, Triple Summer Rewards: Win The Herbalgy Trophy Tickets!HONG KONG, June 5, 2026...

ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present data and key insights within anaphylaxis, food and respiratory allergy.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedication

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers